DOD A-A-54022-1989 CHLOROQUINE PHOSPHATE TABLETS USP《美国标准氯喹磷酸盐药片》.pdf

《DOD A-A-54022-1989 CHLOROQUINE PHOSPHATE TABLETS USP《美国标准氯喹磷酸盐药片》.pdf》由会员分享，可在线阅读，更多相关《DOD A-A-54022-1989 CHLOROQUINE PHOSPHATE TABLETS USP《美国标准氯喹磷酸盐药片》.pdf（3页珍藏版）》请在麦多课文档分享上搜索。

1、A-A-54022 65 = 7777774 0032837 5 C-bS-035 A-A-54 O 2 2 30 Oct 1989 COMMERCIAL ITEM DESCRIPTION CHLOROQUINE PHOSPHATE TABLETS, USP The General Services Administration has authorized the use of this Commercial Item Description as a replacement for Military Specification MIL-C-37520 which is cancelled.

2、 Salient characteristics: Shall be Chloroquine Phosphate Tablets, USP. Shall contain 500 mg Chloroquine Phosphate per tablet, within the applicable assay limits for the tablets. Shall be in accordance with the requirements of the USP. All ingredients shall be of a pharmaceutical grade. Each tablet s

3、hall be marked/embossed with a product identification code to identify the active ingredient(s1, strength, and manufacturer. The materials used in marking/embossing the dosage forms shall be acceptable to the FDA. The actual code used for the product shall be left to the discretion of the supplier.

4、Workmanship. detract from their appearance or impair their serviceability. The tablets shall be free from defects which- Unit. Bottle (BT). One bottle containing 500 tablets, as specified, constitutes one unit. Contractor certification. The contractor shall certify that the product offered meets the

5、 salient characteristics of this description and conforms to the producers own drawings, specifications, standards, and quality assurance practices. The Government reserves the right to require proof of such conformance prior to first delivery and thereafter as may be otherwise provided for under th

6、e provisions of the contract. AMSC/NA FSC 6505 DISTRIBUTION STATEMENT A. Approved for public release; distribution is unlimited. THIS DOCUMENT CONTAINS 3 PAGES. - Provided by IHSNot for ResaleNo reproduction or networking permitted without license from IHS-,-,-A-A-5 4 O 2 2 Regulatory requirements.

7、Federal Food, Drug and Cosmetic Act. f the product covered by this document hac been determined by the U.S. Food and Drug Administration to be under its jurisdiction, the offeror/contractor shall comply, and be responsible for compliance by its subcontractors/suppliers, with the requirements of the

8、Federal Food, Drug and Cosmetic Act, as amended, and iegulations promulgated thereunder. In addition, the sEEeiaz/contractor shall comply, and be responsibe for compliance by its subcontractors/suppliers, with the requirements o all other applicable Federal, State, and local statutes, ordinances, an

9、8 regulations, Recovered materials. The offeror/contractor is encouraged to use recovered material in accordance with Public Law 94-580, as amended, and as implemented by Federal Acquisition Regulation Subpart 23.4 to the maximum extent practical. Frecervation, packaging, packing, labeling, and mark

10、ing. Unless otherwise specified, preservation, packaging, and packing shal be to a degree o protection to preclude damage to containers and/or contents thereoE under normal shipping conditions, handling, etc:, involving shipment from the supply source to the receiving activity, plus reshipment from

11、receiving activity, an shall conform to applicable carriers rules and regulations. Intermediate and exterior package quantities and labeling and marking shall be as specified in the contract and/or order. NOTE: The following National Stock Kumber is covered by this document: NSN 6505-00-117-6450 - I

12、TEM IDENTIFICATION CHLOROQUINE PHOSPHATE TABLETS, USP 500 mg, 500s Ordering data, Expiration dating required, intermediatdexterior package quantities and labeling and marking must be specified in the contract and/or order. Provided by IHSNot for ResaleNo reproduction or networking permitted without

13、license from IHS-,-,-A-A-54022 65 W 7999774 0032839 9 A-A-54 O 22 MILITARY INTERESTS: Custodians: Army - MD Navy - MS Air Force - 03 PREPARING ACTIVITY: CIVIL AGENCY COORDINATING ACTIVITIES: VA-OSS PHS FDA-MPQAS DD - Ml3 Agent: DLA-DM PGC 41842 3 Project No. 6505-2985 Provided by IHSNot for ResaleNo reproduction or networking permitted without license from IHS-,-,-